Anti-CD33 Recombinant Antibody (Lintuzumab) (CAT#: TAB-756)
Recombinant humanized (from mouse) antibody expressed in CHO binding to human CD33. Lintuzumab is a humanized monoclonal antibody used in the treatment of cancer.
Specific Inquiry
Figure 1 Reductions in bone marrow blasts were seen at all dose levels.
Percentage change in bone marrow blasts after treatment with sequential cytarabine and 213 Bi-lintuzumab in 26 evaluable patients.
Rosenblat, T. L., McDevitt, M. R., Mulford, D. A., Pandit-Taskar, N., Divgi, C. R., Panageas, K. S., ... & Larson, S. M. (2010). Sequential cytarabine and α-particle immunotherapy with bismuth-213–lintuzumab (HuM195) for acute myeloid leukemia. Clinical Cancer Research, 1078-0432.
FC
Figure 2 Flow cytometry-based cytotoxicity assay for quantification of AMG330-specific lysis of myeloid cells.
The CD33+ cell line U937 was co-incubated for 24 h with MNC from a healthy donor at an E:T ratio of 1:1 (referred to CD3+ T-cell) in the presence of AMG330 or Control Ab constructs. Dot plots are gated on live, single, CD45+ cells and show CD13+ CD14+ monocytes in blue, donor CD3+ T-cells in green and CD56+ CD14+ U937 target cells in orange. The percentage of respective populations in culture at baseline and after 24 h is given in the table.
Aigner, M., Feulner, J., Schaffer, S., Kischel, R., Kufer, P., Schneider, K., ... & Mackensen, A. (2013). T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia, 27(5), 1107.
Figure 3 The effect of pre-stimulation of autologous T-cells on AMG330-mediated redirected lysis of primary autologous AML blasts.
AML samples were co-cultured for 144 h in the presence of 1 ng/ml AMG330 (CD33 BiTE), 1 ng/ml Control BiTE, or no BiTE. CD8+ T-cells were harvested from these cultures and incubated for the indicated time points together with a second MNC sample from the same patient at an E:T ratio of 1:1. A mean of four independent experiments from four different AML patients±s.d. is shown.
Aigner, M., Feulner, J., Schaffer, S., Kischel, R., Kufer, P., Schneider, K., ... & Mackensen, A. (2013). T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia, 27(5), 1107.
Specifications
- Immunogen
- The details of the immunogen for this antibody are not available.
- Host Species
- Mouse
- Derivation
- Humanized (from mouse)
- Type
- IgG1 - kappa
- Species Reactivity
- Human
- Applications
- IF, IP, Neut, FuncS, ELISA, FC, ICC
- Trade name
- zamyl/smart
- CAS
- 166089-32-3
- Generic Name
- lintuzumab
- Related Disease
- Acute myeloid leukemia (AML)
Product Property
- Purity
- >95.0%, determined by analysis by RP-HPLC & analysis by SDS-PAGE.
- Storage
- Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing of samples.
Applications
- Application Notes
- The CD33 antibody has been reported in applications of Activ, FC, Stim.
Target
- Alternative Names
- lintuzumab;zamyl/smart;166089-32-3;SGN-33;HuM195;Actimab-A;Lintuzumab-Ac-225;SGN-33;CD33;CD33 molecule;CD33 antigen (gp67);myeloid cell surface antigen CD33;FLJ00391;p67;sialic acid binding Ig like lectin 3;SIGLEC 3;SIGLEC3;gp67;sialic acid binding Ig-lik
- Gene ID
- 945
- UniProt ID
- P20138
Related Resources
Please refer to Lintuzumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Lintuzumab.
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Lintuzumab"
Afuco™ Anti-CD33 ADCC Recombinant Antibody (Lintuzumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized (from mouse) antibody expressed in CHO binding to human CD33. Lintuzumab is a humanized monoclonal antibody used in the treatment of cancer.
See other products for "CD33"
Select a product category from the dropdown menu below to view related products.
Please select product type
Single-domain Antibody
Humanized Antibody
Immunotoxin
Human Antibody
Mouse Antibody
Fab Glycosylation
MHC Tetramer for Cancer
Blocking Antibody
Rabbit Monoclonal Antibody
Chimeric Antibody
Recombinant Antibody
scFv Fragment Antibody
ADCC Enhanced Antibody
Fab Fragment Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| NAB-321-sdAb | Recombinant Anti-human CD33 VHH Single Domain Antibody | WB, IP, ChiP, Neut, ELISA | Llama VHH |
Customer Reviews and Q&As
Customer Review
Q&As
-
Ideal for CD33 Research
The Anti-CD33 Therapeutic Antibody (ZAMYL) has been excellent for our CD33 studies. Its specificity and sensitivity are top-notch, providing clear and reliable results. This antibody has significantly improved the accuracy of our experiments and saved us a lot of troubleshooting time. -
Reliable in Immunoassays
We incorporated this antibody into our immunoassays, and it has been a great asset. The specificity for CD33 is precise, allowing for accurate detection and analysis. The reliable performance has made it an invaluable tool in our lab. -
Consistent and High-Quality
This antibody has proven to be consistent and high-quality in our assays. The reproducible results and strong affinity for CD33 have significantly improved our experiments, making it a crucial part of our research toolkit. The consistent performance has greatly enhanced our data quality.
Popular products with customers
Application: FC, IP, ELISA, Neut, FuncS, IF, ICC
Application: IP, IF, FuncS, FC, Neut, ELISA, ICC
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
Application: WB, FC, IP, ELISA, Neut, FuncS, IF
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: IP, IF, FuncS, FC, Neut, ELISA, IHC
Application: FC, IB, Block, Inhib, FuncS, ELISA, FACS, IP, IF
Application: ELISA, FC, WB, FuncS
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
